GT-101(Suzhou Gravel Biotechnology)

The companies will produce a domestically manufactured alternative to the immune-regulating cytokine IL-2 in T-cell therapy. Credit: Anusorn Nakdee/Shutterstock.com. Clinical-stage cell therapy company Shanghai Grit Biotechnology (GRIT) has formed a strategic partnership with Quangang Pharmaceutical (Quangang) to enhance research and development in T-cell therapy for solid tumour patients in China. Recommended Buyer's Guides Buyer's Guide Leading Guide to Compliance Software for the Pharmaceutical Industry Buyer's Guide Top Guide for Cleanrooms and Cleanroom Flooring The partnership’s primary goal is to develop a globally standardised IL-2 for solid tumour patients undergoing T-cell therapy. It will focus on localising this standard with affordable pricing for Chinese patients. The collaboration will concentrate on broadening the indications of Quanqi (125SER) Interleukin-2 (IL-2) products for solid tumours. Quanqi (125SER) is a marketed human Interleukin-2 used in treating solid tumours including renal cell carcinoma, breast cancer, melanoma, bladder cancer, colorectal cancer, liver cancer, lymphoma and lung cancer. See Also: MSD agrees to acquire EyeBio for up to $3bn Merck introduces sterility testing solution for pharma quality control The partnership aims to produce a domestically manufactured alternative to the globally acknowledged immune-regulating cytokine IL-2 in T-cell therapy. GRIT plans to utilise its extensive experience in T-cell therapy to accelerate the development and commercialisation of cell therapy products through the collaboration. Both GRIT and Quangang believe that their joint efforts will soon enable a broader range of Chinese patients to access advanced and effective T-cell treatments, along with an affordable local IL-2 product. GRIT’s non-gene-engineered tumour infiltrating lymphocytes (TILs) programme, GT101, is in a Phase II (pivotal) trial with plans for a biologics licence application (BLA) filing by 2025. In 2023 Grit secured more than $60m (436.72m yuan) in a Series B funding round to support the development of its pipeline programmes. China International Capital Corporation led the financing round, which saw investments from Qianhai Ark, Liando Group, Yuanhe Capital and HeFangTian Venture Partnership. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva . Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content. Free Whitepaper Cell and gene therapies: Pipe dream to pipeline The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead. Thank you. You will receive an email shortly. Please check your inbox to download the Whitepaper. By Cytiva Thematic By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy

SHANGHAI, May 31, 2024 /PRNewswire/ -- Shanghai Grit Biotechnology Co., Ltd. (GRIT) and Shandong Quangang Pharmaceutical Co., Ltd. (Quangang) announced the establishment of a formal strategic partnership to leverage both parties' R&D capabilities in innovative T-cell therapy. The objective is to jointly develop a globally standardized IL-2 for solid tumor patients receiving T-cell therapy, aiming to localize the global standard IL-2 with accessible prices for Chinese patients. The focus of the collaboration will be on expanding the indications of Quanqi (125SER) Interleukin-2 (I) products for solid tumors. Quanqi (125SER), as a domestically marketed human Interleukin-2, is primarily used in the treatment of solid tumors such as renal cell carcinoma, melanoma, breast cancer, bladder cancer, liver cancer, colorectal cancer, lymphoma, and lung cancer, etc. Both parties will collaborate to develop a domestically produced substitute to the globally recognized immune-regulating cytokine IL-2 in T-cell therapy, addressing the significant unmet medical needs for Chinese cancer patients. Grit is a clinical stage cell therapy company leading the tumor infiltrating lymphocytes (TILs) therapy development in China. Grit's non-gene-engineered TIL program GT101 is in Phase 2 (pivotal) trial -- it is the fastest TIL pipeline in China and plans for BLA filing in 2025. Quangang Pharmaceutical is a leading domestic biopharmaceutical company dedicated to the research and development of genetic medicines, boasting GMP facilities and a specialized biotechnology research institute. Both parties have rich technical expertise and product development experience, along with a strong reputation and influence in the biopharmaceutical field in China. Through this collaboration, GRIT will leverage its extensive experience in T cell therapy to expedite the advancement and commercialization of cell therapy products, providing a broader range of options and instilling hope for a greater number of solid tumor patients in the Chinese market. Both parties affirm that through their joint efforts, there is anticipation for a broader spectrum of Chinese patients to soon gain access to advanced and efficacious T-cell treatment options with the affordable local IL-2 product. SOURCE Grit Biotechnology